Medications
Drugs that act on the adipocyte directly: GLP-1 receptor agonists, thiazolidinediones, and lipodystrophy treatments.
Reviews white-to-beige adipocyte transdifferentiation mechanisms and current pharmacological strategies including beta-3 agonists, thyroid hormone analogs, and FGF21 mimetics targeting browning for obesity treatment.
Wilding et al. 2021. Semaglutide 2.4 mg weekly produced 14.9% mean weight loss vs 2.4% placebo over 68 weeks. First major trial establishing GLP-1RA as primary obesity pharmacotherapy.
Aronne LJ et al. 2025. Tirzepatide (GIP+GLP-1 dual agonist) produced superior weight loss to semaglutide in head-to-head trial; 47% of tirzepatide patients achieved 25% or more weight loss.
Tontonoz et al. 1994 (extended). TZDs work because PPARgamma is the master adipogenic regulator; activating it redirects lipid to adipose depots and improves systemic insulin sensitivity.
Maeda et al. 2001. TZDs increase adiponectin secretion from adipocytes as a primary mechanism of their insulin-sensitizing effect, independent of weight loss.
Brown et al. 2012. Metreleptin (recombinant leptin) restores insulin sensitivity and corrects hypertriglyceridemia in leptin-deficient lipodystrophy; the clearest proof of leptin's metabolic role in humans.
Davidson et al. 1999. Orlistat inhibits pancreatic lipase, reducing dietary fat absorption by about 30%; acts upstream of the adipocyte by limiting substrate delivery.
Schauer et al. 2017. Roux-en-Y gastric bypass and sleeve gastrectomy produced superior glycemic control to medical therapy alone at 5 years; remission rates 29% and 23% respectively vs 5% medical.
Current pharmacologic strategies to induce beige adipogenesis, including mirabegron (beta-3 agonist approved for OAB, shown to activate BAT in humans) and experimental approaches.
Jastreboff et al. 2023. Retatrutide produced up to 24.2% weight loss at 48 weeks in phase 2, the highest reported for a pharmacologic agent to date.
A significant subset of patients loses no weight or rebounds on GLP-1RAs. The fat cell's role in this resistance is not yet understood and is an active gap in the field.
2026 proposal: macrophage polarization in adipose tissue is a druggable target; shifting from M1-like to M2-like states in fat reduces local and systemic inflammation in obesity.